Aduro Biotech Appoints Hans van Eenennaam Executive Vice President Antibody Research and Site Head, Aduro Biotech Europe
March 05 2018 - 4:01PM
Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Hans van
Eenennaam, Ph.D. has been promoted to executive vice president
antibody research and site head of Aduro Biotech Europe. In his new
role, Hans will lead antibody research and oversee the day to day
operations of Aduro Biotech Europe.
“Hans continues to be an invaluable member of the Aduro team,”
said Stephen T. Isaacs, chairman, president and chief executive
officer of Aduro Biotech, Inc. “Given Hans’ long history and
expertise in the field of monoclonal antibodies, including
inventorship of our anti-APRIL antibody, BION-1301, and the
anti-CD27 antibody licensed to Merck, we look forward to Hans’
leadership in the discovery of novel antibody targets and their
advancement through development.”
Prior to its acquisition by Aduro in 2015, Dr. van Eenennaam
served as chief operating officer of BioNovion, a company he
co-founded in 2011 to focus on the development of innovative
therapeutic antibodies in the field of immune oncology. Earlier in
his career, he held numerous positions of increasing responsibility
at Organon in Oss, Netherlands, and the Organon Research Center in
Cambridge, Massachusetts, which was acquired by Schering-Plough
Corporation in 2007 and later by Merck & Co. He led the
discovery and development of therapeutic monoclonal antibodies and
small molecule entities in the field of oncology and immunology.
While at Organon, Dr. van Eenennaam, in cooperation with a team of
scientists, discovered pembrolizumab (Keytruda®), a humanized
therapeutic antibody acquired by Merck and approved in 2014 by the
U.S. Food and Drug Administration for the treatment of melanoma and
subsequently for additional indications including, non-small cell
lung cancer and head and neck cancer. In 2016, he and colleagues
were honored by the Intellectual Property Owner’s Association with
the 43rd Annual Inventor of the Year Award. He is named as inventor
on twelve pending and granted patent families, including the
patents claiming Keytruda, and author on over 25 publications. Dr.
van Eenennaam received his doctorate in autoimmune biochemistry
(cum laude) from Radboud University in Nijmegen, Netherlands. Dr.
van Eenennaam currently sits on the board of directors for
Lygature, a non-profit organization that independently enables
public-private partnerships between large corporates, smaller
companies and academia and helps MedTech and Pharma professionals
to work together. He holds a second board of directors position at
a privately-held Germany-based company focusing on immune
oncology.
About Aduro Aduro Biotech, Inc. is an
immunotherapy company focused on the discovery, development and
commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's STING Pathway
Activator platform is designed to activate the STING receptor in
immune cells, resulting in a potent tumor-specific immune response.
ADU-S100 is the first STING Pathway Activator compound to enter the
clinic and is currently being evaluated in both a Phase 1
monotherapy study as well as a Phase 1b combination study with an
anti-PD1 immune checkpoint inhibitor. Aduro’s B-select monoclonal
antibody platform is comprised of a number of immune modulating
assets in research and development, including BION-1301, an
anti-APRIL antibody. Aduro's pLADD program is based on proprietary
attenuated strains of Listeria that have been engineered to express
tumor neoantigens that are specific to an individual patient’s
tumor. Other Listeria strains for lung and prostate cancers are
being advanced by a partner. Aduro is collaborating with leading
global pharmaceutical companies to expand its products and
technology platforms. For more information, please visit
www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, the potential for our technology
platforms, plans, and the potential for eventual regulatory
approval of our product candidates. In some cases, you can identify
these statements by forward-looking words such as “may,” “will,”
“continue,” “plan,” “anticipate,” “intend,” “could,” “project,”
“seek,” “expect,” “position” or the negative or plural of these
words or similar expressions. Forward-looking statements are
not guarantees of future performance and are subject to risks and
uncertainties that could cause actual results and events to differ
materially from those anticipated, including, but not limited to,
our history of net operating losses and uncertainty regarding our
ability to achieve profitability, our ability to develop and
commercialize our product candidates, our ability to use and expand
our technology platforms to build a pipeline of product candidates,
our ability to obtain and maintain regulatory approval of our
product candidates, our ability to operate in a competitive
industry and compete successfully against competitors that have
greater resources than we do, our reliance on third parties, and
our ability to obtain and adequately protect intellectual property
rights for our product candidates. We discuss many of these
risks in greater detail under the heading “Risk Factors” contained
in our quarterly report on Form 10-Q for the quarter ended December
31, 2017, which is on file with the Securities and Exchange
Commission. Any forward-looking statements that we make in this
press release speak only as of the date of this press release. We
assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
Contact: |
Media Contact: |
Jennifer Lew |
Aljanae Reynolds |
Chief Financial
Officer |
510 809 2452 |
510 809-4816 |
press@aduro.com |
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Sep 2023 to Sep 2024